CompletedPhase 4NCT01798992
Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
Studying Non-familial rare disease with dilated cardiomyopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Colorado, Denver
- Principal Investigator
- Michael R Bristow, MD PhDUniversity of Colorado School of Medicine
- Intervention
- Carvedilol(drug)
- Enrollment
- 56 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2000 – 2009
Study locations (2)
- University of Colorado Hospital, Denver, Colorado, United States
- University of Utah Medical Center, Salt Lake City, Utah, United States
Collaborators
National Heart, Lung, and Blood Institute (NHLBI) · GlaxoSmithKline · AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01798992 on ClinicalTrials.govOther trials for Non-familial rare disease with dilated cardiomyopathy
Additional recruiting or active studies for the same condition.
See all trials for Non-familial rare disease with dilated cardiomyopathy →